Advances in genomic research on hepatitis C virus with a useful tool, replicon system

Keio Journal of Medicine

Volumn 57, Issue 2, 2008, Pages 75-83

  Nakamura, Mitsuyasu ^a   Saito, Hidetsugu ^a,b   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Hepatitis C virus; Lipid raft; Rb; Replicon; VX950

Indexed keywords

4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; 5 CYCLOPROPYL 2 (4 FLUOROPHENYL) 6 [N (2 HYDROXYETHYL)METHANESULFONAMIDO] N METHYLBENZOFURAN 3 CARBOXAMIDE; A 689; A 831; A 837093; ANTIVIRUS AGENT; BILB 1941; CASTANOSPERMINE 6 BUTYRATE; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DEBIO 25; E2 MONOCLONAL ANTIBODY; GS 9190; HEPATITIS C ANTIBODY; INTERFERON; ITMN 191; MK 608; MONOCLONAL ANTIBODY; MYOCRICIN; N [3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL] 3 [2 (3 TERT BUTYLUREIDO) 3,3 DIMETHYL 1 OXOBUTYL] 6,6 DIMETHYL 3 AZABICYCLO[3.1.0]HEXANE 2 CARBOXAMIDE; PEGINTERFERON; PEGINTERFERON ALPHA2B; R 1656; R 7128; RIBAVIRIN; SMALL INTERFERING RNA; TELAPREVIR; TOLL LIKE RECEPTOR 9 AGONIST; UNINDEXED DRUG; VALOPICITABINE; VIRUS RNA;

CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CLINICAL TRIAL; GENE REPLICATION; GENOMICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MOLECULAR CLONING; NONHUMAN; RB GENE; REPLICON; REVIEW; RNA REPLICATION; RNA SYNTHESIS; UNSPECIFIED SIDE EFFECT; VIRUS PARTICLE; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; GENOME, VIRAL; HEPACIVIRUS; HUMANS; RNA, VIRAL; VIRUS REPLICATION;

EID: 47249127753     PISSN: 00229717     EISSN: 18801293     Source Type: Journal    
DOI: 10.2302/kjm.57.75     Document Type: Review

References (69)

1. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K: Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990; 87: 9524-9528
2. Tanaka T, Kato N, Cho MJ, Shimotohno K: A novel sequence found at the 3′ terminus of hepatitis C virus genome. Biochem Biophys Res Commun 1995; 215: 744-749
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
4. Kumagai N, Kaneko F, Tsunematsu S, Tsuchimoto K, Tada S, Saito H, Hibi T: Complexity of the HVAR-1 quasispecies and disease activity in patients with hepatitis C. Eur J Clin Invest 2007; 37: 566-572
5. N Enomoto, I Sakuma, Y Asahina, M Kurosaki, T Murakami, C Yamamoto, N Izumi, F Marumo, C Sato: Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96: 224-230
6. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81
7. Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Hamano K, Izumi N, Sato C, Watanabe M: Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. Virology 2003; 311: 376-383
8. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362
9. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM: Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 570-574
10. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113
11. Kishine H, Sugiyama K, Hijikata M, Kato N, Takahashi H, Noshi T, Nio Y, Hosaka M, Miyanari Y, Shimotohno K: Subgenomic replicon derived from a cell line infected with the hepatitis C virus. Biochem Biophys Res Commu 2002; 293: 993-999
12. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM: Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181-3190
13. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T: Efficient replication of the genotype 2a hepatitis c virus subgenomic replicon. Gastroenterology 2003; 125: 1808-1817
14. Ikeda M, Yi M, Li K, Lemon SM: Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002; 76: 2997-3006.
15. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R: Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001; 75: 1437-1449
16. Kumagai N, Takahashi N, Kinoshita M, Tsunematsu S, Tsuchimoto K, Saito H, Ishii H, Hibi T: Polymorphism of NS5B protein relates to early clearance of hepatitis C virus by interferon plus ribavirin: a pilot study. J Viral Hepat 2004; 11: 225-235
17. Nakamura M, Saito H, Ikeda M, Tada S, Kumagai N, Kato N, Shimotohno K, Hibi T: Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment. J Med Virol 2008; 80: 632-639
18. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM: Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 2003; 77: 3181-3190
19. Pietschmann T, Lohmann V, Kaul A, Kriegeerr N, Rinck G, Rutter G, Strand D, Bartenschlager R: Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002; 76: 4008-4021
20. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626
21. Tscherne DM, Jones CT, Evans MJ, Lindenbach BD, McKeating JA, Rice CM: Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol 2006; 80: 1734-1741
22. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, Heathcote J, Rice CM: Silencing of UPD18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006; 131: 1584-1591
23. Schwer B, Ren S, Pietschmann T, Kartenbeck J, Kaehicke K, Bartenschlager R, Yen TS, Ott M: Targeting of hepatitis C virus core protein to mitochondria through a novel C-terminal localization motif. J Virol 2004; 78: 7958-7968
24. Lee SH, Kim YK, Kim CS, Seol SK, Kim J, Cho S, Song YL, Bartenschlager R, Jang SK: E2 of hepatitis C virus inhibits apoptosis. J Immunol 2005; 175: 8226-8235
25. Miyanari Y, Hijikata M, Yamaji M, Hosaka M, Takahashi H, Shimotohno K: Hepatitis C virus non-structural proteins in the probable membranous compartment function in viral genome replication. J Biol Chem 2003; 278: 50301-50308
26. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, Moradpour D: Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003; 77: 5487-5492
27. Schwartz M, Chen J, Janda M, Sullivan M, den Boon J, Ahlquist P: A positive-strand RNA virus replication complex parallels form and function of retrovirus capsids. Mol Cell 2002; 9: 505-514
28. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T: Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 2003; 125: 1808-1817
29. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796
30. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV: Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294-9299
31. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A 2006; 103: 3805-3809
32. Morikawa K, Xhao Z, Date T, Miyamoto M, Murayama A, Akazawa D, Tanabe J, Sone S, Wakita T: The role of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles. J Med Virol 2007; 79: 714-723
33. Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H: Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005; 43: 186-191
34. Saito H, Tada S, Ebinuma H, Ishii H, Kashiwazaki K, Takahashi M, Tsukada N, Nishida J, Tanaka S, Shiozaki H, Hibi T: Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006; 44:3562-3568
35. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K: Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288
36. Loor F, Tiberghien F, Wenandy T, Didier A, Traber R: Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter. J Med Chem 2002; 45: 4598-4612
37. Ye J, Wang C, Sumpter R, Jr., Brown MS, Goldstein JL, Gale M, Jr: Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 2003; 100: 15865-15870
38. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M: Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567-572
39. Akiyama H, Yoshinaga H, Tanaka T, Hiruma K, Tanikawa S, Sakamaki H, Onozawa Y, Wakita T, Kohara M: Effects of cyclosporin A on hepatitis C virus infection in bone marrow transplant patients. Bone Marrow Transplantation Team. Bone Marrow Transplant 1997; 20: 993-995
40. Goto K, Watashi K, Murata T, Hishiki T, Hijikata M, SHimotohno K: Evaliation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporine A, and NIM 811. Biochem Biophys Res Commun 2006; 343: 879-884
41. Umehara T, Sudoh M, Yasui F, Matsuda C, Hayashi Y, Chayama K, Kohara M: Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun 2006; 346: 67-73
42. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 2006; 44: 117-125
43. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Cartier M, Cordingley MG, Faucher AM, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL, Llinas-Brunet M: An NS3 protease inhibitor with antiviral effects in human s infected with hepatitis C virus. Nature 2003; 426: 186-189
44. Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL, Casper DJ, Kaura A, Baker A, Greenwood C, Gutshall LL, Maley D, DelVecchio A, Macarron R, Hofmann GA, Alnoah Z, Cheng HY, Chan G, Khandekar S, Keenan RM, Sarisky RT: Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 2002; 277: 38322-38327
45. Foy E, Li K, Wang C, Sumpter R, Ikeda M, Lemon SM, Gale M: Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300: 1145-1148
46. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauffman R, Alam J, Jansen PL: Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002
47. Summa V. VX-950 (Vertex/Mitsubishi). Curr Opin Investig Drugs 2005; 8: 831-837
48. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S: SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007; 132: 1270-1278
49. Perelson AS, Herrmann E, Micol F, Zeuzem S: New kinetic models for the hepatitis C virus. Hepatology 2005; 42: 749-754
50. Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, Bogen SL, Saksena AK, Njoroge FG, Veselenak RL, Pyles RB, Bourne N, Malcolm BA, Lemon SM: Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 2006; 28: 8205-8215
51. Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD: In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005; 280: 36784-36791
52. Carroll SS, Olsen DB: Nucleoside analog inhibitors of hepatitis C virus replicationInfect. Disord Drug Targets 2006; 6: 17-29
53. Pierra C, Amador A, Benzaria S, Cretton-Scott E, D'Amours M, Mao J, Mathieu S, Moussa A, Bridges EG, Standring DN, Sommadossi JP, Storer R, Gosselin G: Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 2006; 49: 6614-6620
54. McHutchison J, Ghalib R, Lawitz E, Freilich B, Kwo P, Masciari F, Himes JL, Al-Adhami M, Bacon B: Early Viral Response to CpG 10101, a new investigational antiviral TLR9 agonist, in combination with pegylated interferon and/or ribavirin, in prior relapse HCV responders: preliminary report of a randomized phase 1 study. Gastroenterology 2006; 130: S1062
55. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H: Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO reports 2003; 4, 6: 602-608
56. Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R: A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 1995; 374: 81-84
57. Liu Y, April L. Colosimo AL, Yang XJ, Liao D: Adenovirus E1B 55-Kilodalton Oncoprotein Inhibits p53 Acetylation by PCAF. Mol Cell Biol 2000; 20: 5540-5553
58. Ariumi Y, Kaida A, Hatanaka M, Shimotohno K: Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain. Biochem Biophys Res Commun 2001; 287: 556-561
59. Ariumi Y, Kaida A, Lin JY, Hirota M, Masui O, Yamaoka S, Taya Y, Shimotohno K: HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene 2000; 19: 1491-1499
60. Patel D, Huang SM, Baglia LA, McCance DJ: The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999; 18: 5061-5072
61. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ: Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275: 6764-6769
62. Watashi K, Hijikata M, Tagawa A, Doi T, Marusawa H, Shimotohno K: Modulation of retinoid signaling by a cytoplasmic viral protein via sequestration of Sp110b, a potent transcriptional corepressor of retinoic acid receptor, from the nucleus. Mol Cell Biol 2003; 23: 7498-7509
63. Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H: Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003; 106: 334-341
64. Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins, JR: The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053-1061
65. Chau BN, Wang JY: Coordinated regulation of life and death by RB. Nat Rev Cancer 2003; 3: 130-138
66. Munakata T, Nakamura M, Liang Y, Li K, Lemon SM: Downregulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 2005; 102: 18159-18164
67. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, Weinberg RA, Harlow E: Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988; 334: 124-129
68. Dyson N, Howley PM, Munger K, Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-937
69. Lee JO, Russo AA, Pavletich NP: Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 1998; 391: 859-865